Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 9 Carcinoma, Hepatocellular 9 Small Cell Lung Carcinoma 8 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Glioblastoma 5 Carcinoma, Transitional Cell 5 Ovarian Neoplasms 4 Advanced Solid Tumor 4 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Follicular 3 Liver Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Neuroendocrine 3 Solid Cancer 2 Small Cell Lung Cancer Extensive Stage 2 Recurrence 2 Neuroendocrine Tumors 2 Lymphoma, Large B-Cell, Diffuse 2

Interventions

Gemcitabine 13 Cisplatin 10 pembrolizumab 7 Oxaliplatin 5 Leucovorin 5 Fluorouracil 5 durvalumab 4 Paclitaxel 4 Nivolumab 3 Injections 3 Immune Checkpoint Inhibitors 3 Capecitabine 3 camrelizumab 2 Docetaxel 2 Cetuximab 2 Carboplatin 2 130-nm albumin-bound paclitaxel 2 tremelimumab 1 surufatinib 1 spartalizumab 1 silmitasertib 1 regorafenib 1 pertuzumab 1 manganese chloride 1 lenvatinib 1 irinotecan sucrosofate 1 folfirinox 1 devimistat 1 derazantinib 1 binimetinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Biliary Tract Neoplasms × atezolizumab × Clear all

NCT05052099 2025-09-29

COMBATBIL

University Hospital, Essen

Phase 1/2 Completed

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡